Technical Analysis for ARRY - Array BioPharma Inc.

Grade Last Price % Change Price Change
grade C 24.545 17.10% 3.59
ARRY closed down 4.12 percent on Monday, May 20, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARRY trend table...

Date Alert Name Type % Chg
Below Lower BB Weakness 17.10%
Lower Bollinger Band Touch Weakness 17.10%
Spinning Top Other 12.28%
20 DMA Resistance Bearish 12.44%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 12.44%
Stochastic Buy Signal Bullish 10.66%
Lower Bollinger Band Touch Weakness 10.66%
Oversold Stochastic Weakness 10.66%
Slingshot Bearish Bearish Swing Setup 13.85%
Lower Bollinger Band Walk Weakness 13.85%

Older signals for ARRY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Chemistry Biopharmaceutical Cancer Pain Nasdaq Chemical Compounds Organic Compounds Treatment Of Cancer Breast Cancer Multiple Myeloma Asthma Inflammatory Diseases Chloroarenes Hepatitis C Phosphoinositide 3 Kinase Inhibitor Metastatic Solid Tumors Gastric Cancer Myelodysplastic Syndromes Binimetinib Her2 Mek Inhibitor
Is ARRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.05
52 Week Low 12.56
Average Volume 2,334,268
200-Day Moving Average 18.1476
50-Day Moving Average 23.1738
20-Day Moving Average 22.3315
10-Day Moving Average 21.803
Average True Range 0.8477
ADX 21.47
+DI 15.8447
-DI 24.2499
Chandelier Exit (Long, 3 ATRs ) 20.9669
Chandelier Exit (Short, 3 ATRs ) 23.2631
Upper Bollinger Band 23.6977
Lower Bollinger Band 20.9653
Percent B (%b) 0.0
BandWidth 12.235631
MACD Line -0.4622
MACD Signal Line -0.3688
MACD Histogram -0.0935
Fundamentals Value
Market Cap 3.59 Billion
Num Shares 171 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -29.11
Price-to-Sales 41.12
Price-to-Book 153.97
PEG Ratio -1.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.04
Resistance 3 (R3) 22.15 21.90 21.86
Resistance 2 (R2) 21.90 21.62 21.85 21.80
Resistance 1 (R1) 21.43 21.46 21.31 21.32 21.74
Pivot Point 21.18 21.18 21.12 21.13 21.18
Support 1 (S1) 20.71 20.90 20.59 20.60 20.18
Support 2 (S2) 20.46 20.74 20.41 20.12
Support 3 (S3) 19.99 20.46 20.06
Support 4 (S4) 19.88